Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 164

1.

CFTR is a tumor suppressor gene in murine and human intestinal cancer.

Than BL, Linnekamp JF, Starr TK, Largaespada DA, Rod A, Zhang Y, Bruner V, Abrahante J, Schumann A, Luczak T, Walter J, Niemczyk A, O'Sullivan MG, Medema JP, Fijneman RJ, Meijer GA, Van den Broek E, Hodges CA, Scott PM, Vermeulen L, Cormier RT.

Oncogene. 2017 Feb 13. doi: 10.1038/onc.2017.3. [Epub ahead of print] No abstract available.

PMID:
28192405
2.

Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.

Pomeroy EJ, Lee LA, Lee RD, Schirm DK, Temiz NA, Ma J, Gruber TA, Diaz-Flores E, Moriarity BS, Downing JR, Shannon KM, Largaespada DA, Eckfeldt CE.

Oncogene. 2016 Dec 19. doi: 10.1038/onc.2016.471. [Epub ahead of print]

PMID:
27991934
3.

Slit-Robo GTPase-Activating Protein 2 as a metastasis suppressor in osteosarcoma.

Marko TA, Shamsan GA, Edwards EN, Hazelton PE, Rathe SK, Cornax I, Overn PR, Varshney J, Diessner BJ, Moriarity BS, O'Sullivan MG, Odde DJ, Largaespada DA.

Sci Rep. 2016 Dec 14;6:39059. doi: 10.1038/srep39059.

4.

Using genome-wide CRISPR library screening with library resistant DCK to find new sources of Ara-C drug resistance in AML.

Kurata M, Rathe SK, Bailey NJ, Aumann NK, Jones JM, Veldhuijzen GW, Moriarity BS, Largaespada DA.

Sci Rep. 2016 Nov 3;6:36199. doi: 10.1038/srep36199.

5.

RALB provides critical survival signals downstream of Ras in acute myeloid leukemia.

Eckfeldt CE, Pomeroy EJ, Lee RD, Hazen KS, Lee LA, Moriarity BS, Largaespada DA.

Oncotarget. 2016 Oct 4;7(40):65147-65156. doi: 10.18632/oncotarget.11431.

6.

Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.

Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, Jena B, Dawson MJ, Kumaresan PR, Su S, Maiti S, Dai J, Moriarity B, Forget MA, Senyukov V, Orozco A, Liu T, McCarty J, Jackson RN, Moyes JS, Rondon G, Qazilbash M, Ciurea S, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Kantarjian H, Keating M, Wierda W, Do KA, Largaespada DA, Lee DA, Hackett PB, Champlin RE, Cooper LJ.

J Clin Invest. 2016 Sep 1;126(9):3363-76. doi: 10.1172/JCI86721. Epub 2016 Aug 2.

7.

CK2 blockade causes MPNST cell apoptosis and promotes degradation of β-catenin.

Kendall JJ, Chaney KE, Patel AV, Rizvi TA, Largaespada DA, Ratner N.

Oncotarget. 2016 Aug 16;7(33):53191-53203. doi: 10.18632/oncotarget.10668.

8.

Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.

Sachs Z, Been RA, DeCoursin KJ, Nguyen HT, Mohd Hassan NA, Noble-Orcutt KE, Eckfeldt CE, Pomeroy EJ, Diaz-Flores E, Geurts JL, Diers MD, Hasz DE, Morgan KJ, MacMillan ML, Shannon KM, Largaespada DA, Wiesner SM.

Haematologica. 2016 Oct;101(10):1190-1199. Epub 2016 Jul 14.

9.

An ShRNA Screen Identifies MEIS1 as a Driver of Malignant Peripheral Nerve Sheath Tumors.

Patel AV, Chaney KE, Choi K, Largaespada DA, Kumar AR, Ratner N.

EBioMedicine. 2016 Jul;9:110-9. doi: 10.1016/j.ebiom.2016.06.007. Epub 2016 Jun 4.

10.

Engineered Swine Models of Cancer.

Watson AL, Carlson DF, Largaespada DA, Hackett PB, Fahrenkrug SC.

Front Genet. 2016 May 9;7:78. doi: 10.3389/fgene.2016.00078. eCollection 2016. Review.

11.

Case-oriented pathways analysis in pancreatic adenocarcinoma using data from a sleeping beauty transposon mutagenesis screen.

Ho YY, Starr TK, LaRue RS, Largaespada DA.

BMC Med Genomics. 2016 Apr 1;9:16. doi: 10.1186/s12920-016-0176-7.

12.

Retroviral insertional mutagenesis identifies the del(5q) genes, CXXC5, TIFAB and ETF1, as well as the Wnt pathway, as potential targets in del(5q) myeloid neoplasms.

Stoddart A, Qian Z, Fernald AA, Bergerson RJ, Wang J, Karrison T, Anastasi J, Bartom ET, Sarver AL, McNerney ME, Largaespada DA, Le Beau MM.

Haematologica. 2016 Jun;101(6):e232-6. doi: 10.3324/haematol.2015.139527. Epub 2016 Mar 4. No abstract available.

13.

Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.

Wu J, Keng VW, Patmore DM, Kendall JJ, Patel AV, Jousma E, Jessen WJ, Choi K, Tschida BR, Silverstein KA, Fan D, Schwartz EB, Fuchs JR, Zou Y, Kim MO, Dombi E, Levy DE, Huang G, Cancelas JA, Stemmer-Rachamimov AO, Spinner RJ, Largaespada DA, Ratner N.

Cell Rep. 2016 Mar 1;14(8):1979-90. doi: 10.1016/j.celrep.2016.01.074. Epub 2016 Feb 18.

14.

Imprinting defects at human 14q32 locus alters gene expression and is associated with the pathobiology of osteosarcoma.

Shu J, Li L, Sarver AE, Pope EA, Varshney J, Thayanithy V, Spector L, Largaespada DA, Steer CJ, Subramanian S.

Oncotarget. 2016 Apr 19;7(16):21298-314. doi: 10.18632/oncotarget.6965.

15.

Divergent clonal selection dominates medulloblastoma at recurrence.

Morrissy AS, Garzia L, Shih DJ, Zuyderduyn S, Huang X, Skowron P, Remke M, Cavalli FM, Ramaswamy V, Lindsay PE, Jelveh S, Donovan LK, Wang X, Luu B, Zayne K, Li Y, Mayoh C, Thiessen N, Mercier E, Mungall KL, Ma Y, Tse K, Zeng T, Shumansky K, Roth AJ, Shah S, Farooq H, Kijima N, Holgado BL, Lee JJ, Matan-Lithwick S, Liu J, Mack SC, Manno A, Michealraj KA, Nor C, Peacock J, Qin L, Reimand J, Rolider A, Thompson YY, Wu X, Pugh T, Ally A, Bilenky M, Butterfield YS, Carlsen R, Cheng Y, Chuah E, Corbett RD, Dhalla N, He A, Lee D, Li HI, Long W, Mayo M, Plettner P, Qian JQ, Schein JE, Tam A, Wong T, Birol I, Zhao Y, Faria CC, Pimentel J, Nunes S, Shalaby T, Grotzer M, Pollack IF, Hamilton RL, Li XN, Bendel AE, Fults DW, Walter AW, Kumabe T, Tominaga T, Collins VP, Cho YJ, Hoffman C, Lyden D, Wisoff JH, Garvin JH Jr, Stearns DS, Massimi L, Schüller U, Sterba J, Zitterbart K, Puget S, Ayrault O, Dunn SE, Tirapelli DP, Carlotti CG, Wheeler H, Hallahan AR, Ingram W, MacDonald TJ, Olson JJ, Van Meir EG, Lee JY, Wang KC, Kim SK, Cho BK, Pietsch T, Fleischhack G, Tippelt S, Ra YS, Bailey S, Lindsey JC, Clifford SC, Eberhart CG, Cooper MK, Packer RJ, Massimino M, Garre ML, Bartels U, Tabori U, Hawkins CE, Dirks P, Bouffet E, Rutka JT, Wechsler-Reya RJ, Weiss WA, Collier LS, Dupuy AJ, Korshunov A, Jones DT, Kool M, Northcott PA, Pfister SM, Largaespada DA, Mungall AJ, Moore RA, Jabado N, Bader GD, Jones SJ, Malkin D, Marra MA, Taylor MD.

Nature. 2016 Jan 21;529(7586):351-7. doi: 10.1038/nature16478. Epub 2016 Jan 13.

16.

CFTR is a tumor suppressor gene in murine and human intestinal cancer.

Than BL, Linnekamp JF, Starr TK, Largaespada DA, Rod A, Zhang Y, Bruner V, Abrahante J, Schumann A, Luczak T, Niemczyk A, O'Sullivan MG, Medema JP, Fijneman RJ, Meijer GA, Van den Broek E, Hodges CA, Scott PM, Vermeulen L, Cormier RT.

Oncogene. 2016 Aug 11;35(32):4179-87. doi: 10.1038/onc.2015.483. Epub 2016 Jan 11.

17.

Coping with cancer genes altered by copy number.

Wolf NK, Largaespada DA, Moriarity BS.

Oncotarget. 2015 Nov 3;6(34):35155-6. doi: 10.18632/oncotarget.6215. No abstract available.

18.

Transposon mouse models to elucidate the genetic mechanisms of hepatitis B viral induced hepatocellular carcinoma.

Chiu AP, Tschida BR, Lo LH, Moriarity BS, Rowlands DK, Largaespada DA, Keng VW.

World J Gastroenterol. 2015 Nov 14;21(42):12157-70. doi: 10.3748/wjg.v21.i42.12157. Review.

19.

RNA sequencing of Sleeping Beauty transposon-induced tumors detects transposon-RNA fusions in forward genetic cancer screens.

Temiz NA, Moriarity BS, Wolf NK, Riordan JD, Dupuy AJ, Largaespada DA, Sarver AL.

Genome Res. 2016 Jan;26(1):119-29. doi: 10.1101/gr.188649.114. Epub 2015 Nov 9.

20.

Sleeping Beauty transposon screen identifies signaling modules that cooperate with STAT5 activation to induce B-cell acute lymphoblastic leukemia.

Heltemes-Harris LM, Larson JD, Starr TK, Hubbard GK, Sarver AL, Largaespada DA, Farrar MA.

Oncogene. 2016 Jun 30;35(26):3454-64. doi: 10.1038/onc.2015.405. Epub 2015 Oct 26.

Supplemental Content

Loading ...
Support Center